Gene-environment interaction models to unmask susceptibility mechanisms in Parkinson's disease

Journal of Visualized Experiments

Volumn , Issue 83, 2014, Pages

  Chou, Vivian P ^a   Ko, Novie ^a   Holman, Theodore R ^b   Manning Boǧ, Amy B ^a  

^a SRI INTERNATIONAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dopamine; Gene environment interactions; GFAP; Iba1; Issue 83; Lipoxygenase; Medicine; Mouse; MPTP; Neurodegeneration; Neuroinflammation; Parkinson's disease; TH; Transgenic

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ISOENZYME; LIPOXYGENASE;

ANIMAL; ARTICLE; DRUG EFFECT; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; METABOLISM; MOUSE; PARKINSON DISEASE; PATHOLOGY; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; ISOENZYMES; LIPOXYGENASE; MICE; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 84907652237     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/50960     Document Type: Article

References (50)

1. Manning-Bog, A. B., & Langston, J. W. Model fusion, the next phase in developing animal models for Parkinson's disease. Neurotox. Res. 11, 219-240 (2007).
2. Vance, J. M., Ali, S., Bradley, W. G., Singer, C., & Di Monte, D. A. Gene-environment interactions in Parkinson's disease and other forms of parkinsonism. Neurotoxicology. 31, 598-602, doi:10.1016/j.neuro.2010.04.007 (2010).
3. Heikkila, R. E., Hess, A., & Duvoisin, R. C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science. 224, 1451-1453 (1984).
4. Chou, V. P., Holman, T. R., & Manning-Bog, A. B. Differential contribution of lipoxygenase isozymes to nigrostriatal vulnerability. Neuroscience. 228, 73-82, doi:10.1016/j.neuroscience.2012.10.009 (2013).
5. Deschamps, J. D., Kenyon, V. A., & Holman, T. R. Baicalein is a potent in vitro inhibitor against both reticulocyte 15-human and platelet 12-human lipoxygenases. Bioorg. Med. Chem. 14, 4295-4301, doi:10.1016/j.bmc.2006.01.057 (2006).
6. Weaver, J. R. et al. Integration of pro-inflammatory cytokines, 12-lipoxygenase and NOX-1 in pancreatic islet beta cell dysfunction. Mol. Cell Endocrinol.358, 88-95, doi:10.1016/j.mce.2012.03.004 (2012).
7. Yigitkanli, K. et al. Inhibition of 12/15-lipoxygenase as therapeutic strategy to treat stroke. Ann. Neurol. 73, 129-135, doi:10.1002/ana.23734 (2013).
8. van Leyen, K. et al. Novel lipoxygenase inhibitors as neuroprotective reagents. J Neurosci. Res. 86, 904-909, doi:10.1002/jnr.21543 (2008).
9. Chu, J., & Pratico, D. 5-lipoxygenase as an endogenous modulator of amyloid beta formation in vivo. Ann. Neurol. 69, 34-46, doi:10.1002/ana.22234 (2011).
10. Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219, 979-980 (1983).
11. Bove, J., & Perier, C. Neurotoxin-based models of Parkinson's disease. Neuroscience. 211, 51-76, doi:10.1016/j.neuroscience.2011.10.057 (2012).
12. Beal, M. F. Neuroprotective effects of creatine. Amino Acids. 40, 1305-1313, doi:10.1007/s00726-011-0851-0 (2011).
13. Jackson-Lewis, V., Blesa, J., & Przedborski, S. Animal models of Parkinson's disease. Parkinsonism Relat. Disord. 18 Suppl 1, S183-185, doi:10.1016/S1353-8020(11)70057-8 (2012).
14. Dauer, W., & Przedborski, S. Parkinson's disease: mechanisms and models. Neuron. 39, 889-909 (2003).
15. Wang, H., Shimoji, M., Yu, S. W., Dawson, T. M., & Dawson, V. L. Apoptosis inducing factor and PARP-mediated injury in the MPTP mouse model of Parkinson's disease. Ann. N.Y. Acad. Sci. 991, 132-139 (2003).
16. Petroske, E., Meredith, G. E., Callen, S., Totterdell, S., & Lau, Y. S. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience. 106, 589-601 (2001).
17. Przedborski, S. et al. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem. 76, 1265-1274 (2001).
18. Thomas, B. et al. Mitochondrial permeability transition pore component cyclophilin D distinguishes nigrostriatal dopaminergic death paradigms in the MPTP mouse model of Parkinson's disease. Antioxid. Redox. Signal. 16, 855-868, doi:10.1089/ars.2010.3849 (2012).
19. Sonsalla, P. K., & Heikkila, R. E. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur. J. Pharmacol. 129, 339-345 (1986).
20. Di Monte, D. A. et al. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov. Disord. 15, 459-466 (2000).
21. Lee, K. W. et al. Apoptosis signal-regulating kinase 1 mediates MPTP toxicity and regulates glial activation. PLoS One. 7, e29935, doi:10.1371/journal.pone.0029935 (2012).
22. Jackson-Lewis, V., & Przedborski, S. Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2, 141-151, doi:10.1038/nprot.2006.342 (2007).
23. Bolin, L. M., Strycharska-Orczyk, I., Murray, R., Langston, J. W., & Di Monte, D. Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice. J. Neurochem. 83, 167-175 (2002).
24. Manning-Bog, A. B. et al. Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter. Neurobiol. Dis.27, 141-150, doi:10.1016/j.nbd.2007.03.014 (2007).
25. Quik, M., & Di Monte, D. A. Nicotine administration reduces striatal MPP+ levels in mice. Brain Res. 917, 219-224 (2001).
26. Markey, S. P., Johannessen, J. N., Chiueh, C. C., Burns, R. S., & Herkenham, M. A. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature. 311, 464-467 (1984).
27. Heikkila, R. E., Manzino, L., Cabbat, F. S., & Duvoisin, R. C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature. 311, 467-469 (1984).
28. Crampton, J. M., Runice, C. E., Doyle, T. J., Lau, Y. S., & Wilson, J. A. MPTP in mice: treatment, distribution and possible source of contamination. Life Sci. 42, 73-78 (1988).
29. Yang, S. C., Markey, S. P., Bankiewicz, K. S., London, W. T., & Lunn, G. Recommended safe practices for using the neurotoxin MPTP in animal experiments. Lab. Anim. Sci. 38, 563-567 (1988).
30. Lau, Y. S., Novikova, L., & Roels, C. MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact. Neuroscience research. 52, 371-378, doi:10.1016/j.neures.2005.04.010 (2005).
31. Satoh, N. et al. Central hypothermic effects of some analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridinium ion (MPP+). Neurosci. Lett. 80, 100-105 (1987).
32. Fernagut, P. O. et al. Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse.61, 991-1001, doi:10.1002/syn.20456 (2007).
33. Manning-Bog, A. B., McCormack, A. L., Purisai, M. G., Bolin, L. M., & Di Monte, D. A. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J. Neurosci. 23, 3095-3099 (2003).
34. Richfield, E. K. et al. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp. Neurol. 175, 35-48, doi:10.1006/exnr.2002.7882 (2002).
35. Thomas, B. et al. Resistance to MPTP-neurotoxicity in alpha-synuclein knockout mice is complemented by human alpha-synuclein and associated with increased beta-synuclein and Akt activation. PloS one. 6, e16706, doi:10.1371/journal.pone.0016706 (2011).
36. Smeyne, M., Goloubeva, O., & Smeyne, R. J. Strain-dependent susceptibility to MPTP and MPP(+)-induced parkinsonism is determined by glia. Glia. 34, 73-80 (2001).
37. Hamre, K., Tharp, R., Poon, K., Xiong, X., & Smeyne, R. J. Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus. Brain Res. 828, 91-103 (1999).
38. Sedelis, M. et al. MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav. Genet. 30, 171-182 (2000).
39. Boyd, J. D. et al. Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta. Brain Res. 1175, 107-116, doi:10.1016/j.brainres.2007.07.067 (2007).
40. Ookubo, M., Yokoyama, H., Kato, H., & Araki, T. Gender differences on MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in C57BL/6 mice. Molecular and cellular endocrinology. 311, 62-68, doi:10.1016/j.mce.2009.07.011 (2009).
41. Kenchappa, R. S., Diwakar, L., Annepu, J., & Ravindranath, V. Estrogen and neuroprotection: higher constitutive expression of glutaredoxin in female mice offers protection against MPTP-mediated neurodegeneration. FASEB J. 18, 1102-1104, doi:10.1096/fj.03-1075fje (2004).
42. Jackson-Lewis, V., Jakowec, M., Burke, R. E., & Przedborski, S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration. 4, 257-269 (1995).
43. Mizuno, Y., Sone, N., & Saitoh, T. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain. J. Neurochem. 48, 1787-1793 (1987).
44. Nicklas, W. J., Youngster, S. K., Kindt, M. V., & Heikkila, R. E. MPTP, MPP+ and mitochondrial function. Life Sci. 40, 721-729 (1987).
45. Nicklas, W. J., Vyas, I., & Heikkila, R. E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36, 2503-2508 (1985).
46. Wu, D. C. et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.J. Neurosci. 22, 1763-1771 (2002).
47. Kurkowska-Jastrzebska, I., Wronska, A., Kohutnicka, M., Czlonkowski, A., & Czlonkowska, A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp. Neurol. 156, 50-61, doi:10.1006/exnr.1998.6993 (1999).
48. Tatton, N. A., & Kish, S. J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience. 77, 1037-1048 (1997).
49. Furuya, T. et al. Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J Neurosci. 24, 1865-1872, doi:10.1523/JNEUROSCI.3309-03.2004 (2004).
50. Anderson, D. W., Bradbury, K. A., & Schneider, J. S. Neuroprotection in Parkinson models varies with toxin administration protocol. Eur. J. Neurosci. 24, 3174-3182, doi:10.1111/j.1460-9568.2006.05192.x (2006).